Skip to content
MONTEGRE

French Simago Acquires Majority Stake in Romanian Medima

Simago takes control of Medima from Morphosis Capital, Integral Capital Group and co-founder Gheorghe Iana, creating a regional platform in Central and Eastern Europe.

Sources: Forbes Romania, Economica.net, Economedia3 sources ↓|· 2 min read
French Simago Acquires Majority Stake in Romanian Medima
Photo: Forbes Romania

KEY POINTS

  • Simago acquires majority stake in Medima from Morphosis Capital, Integral Capital Group and Gheorghe Iana
  • Deal marks Simago's entry into Central and Eastern Europe
  • Medima operates 34 clinics in 30 Romanian cities
  • Vlad Ardeleanu retains full stake and continues as CEO
  • Morphosis Capital reports 4.3x MOIC and 31% IRR

French medical imaging group Simago has completed the acquisition of a majority stake in Romania's Medima. The sellers were investment funds Morphosis Capital and Integral Capital Group, along with co-founder Gheorghe Iana. The deal marks Simago's entry into Central and Eastern Europe and turns Medima into a regional development platform.

Simago already operates in France, Italy and Romania and has been backed since 2022 by Ardian, a global alternative asset manager with over 200 billion dollars in assets under management or advisory. The group has completed more than 40 acquisitions in the last five years and is one of the main consolidators of the European medical imaging market.

“Medima is a clear proof of the model through which Morphosis Capital creates value.”

— Morphosis Capital

Following the integration of Medima, Simago manages more than 160 medical centres, approximately 2,150 employees and more than 500 radiologists and nuclear medicine specialists. The group handles over five million appointments annually and becomes the third-largest specialised medical imaging provider in Europe.

Medima operates 34 clinics in 30 Romanian cities and grew from a single clinic in Bucharest into a national diagnostic imaging network while under Morphosis Capital's portfolio. Vlad Ardeleanu, Medima's co-founder and chief executive, did not sell any shares and retains his full stake. He remains a shareholder alongside Simago and will continue to lead the company.

Charles-Henry Béglin, president of Simago, said Medima's radiologists now join a medical community of more than 500 doctors and that patients will benefit from strategic partnerships in equipment and artificial intelligence. He added that Simago intends to keep expanding in Europe under medical leadership, with medical act quality as its benchmark.

Morphosis Capital said the transaction generated a 4.3x multiple on invested capital and a 31% internal rate of return for Morphosis Capital Fund I. The fund described Medima as proof of its value-creation model and said the exit confirms its investment approach of identifying early opportunities and building companies that strategic investors want to acquire.

COMMENTS (0)

0/2000

No comments yet. Be the first.

RELATED STORIES

This page was compiled with AI assistance from the outlets named above and passed an automated language check before publication. Montegre has no reporters of its own; the byline names the outlets the story was compiled from. Method and editorial standards